Cascadian's tucatinib delays regrowth of breast cancer by a median of 7.8 months in newly updated study results presented this week.
Monday's disclosure that Puma is adding a second drug to its diarrhea prophylaxis protocol for neratinib-treated patients once again raises concern that the drug is too toxic to be approved.
Puma CEO Alan Auerbach wanted the cash desperately, regardless of Puma's stock price. Get the deal done, even if you have to sell it to the shorts.
Puma Biotechnology (PBYI) is commencing a secondary public offering of stock.